Long-term (5 years), high daily dosage of dietary agmatine--evidence of safety: a case report

J Med Food. 2014 Nov;17(11):1256-9. doi: 10.1089/jmf.2014.0026. Epub 2014 Sep 23.


There is presently a great interest in the therapeutic potential of agmatine, decarboxylated arginine, for various diseases. Recent clinical studies have already shown that oral agmatine sulfate given for up to 3 weeks provides a safe and, as compared with current therapeutics, more effective treatment for neuropathic pain. These studies have ushered in the use of dietary agmatine as a nutraceutical. However, in view of information paucity, assessment of long-term safety of oral agmatine treatment is now clearly required. The authors of this report undertook to assess their own health status during ongoing consumption of a high daily dosage of oral agmatine over a period of 4-5 years. A daily dose of 2.67 g agmatine sulfate was encapsulated in gelatin capsules; the regimen consists of six capsules daily, each containing 445 mg, three in the morning and three in the evening after meals. Clinical follow-up consists of periodic physical examinations and laboratory blood and urine analyses. All measurements thus far remain within normal values and good general health status is sustained throughout the study period, up to 5 years. This case study shows for the first time that the recommended high dosage of agmatine may be consumed for at least 5 years without evidence of any adverse effects. These initial findings are highly important as they provide significant evidence for the extended long-term safety of a high daily dosage of dietary agmatine--a cardinal advantage for its utility as a nutraceutical.

Keywords: agmatine sulfate; dietary ingredients; neuropathies; nutraceuticals.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Agmatine / administration & dosage
  • Agmatine / adverse effects*
  • Agmatine / therapeutic use
  • Diet
  • Dietary Supplements / adverse effects*
  • Female
  • Health Status
  • Humans
  • Male
  • Middle Aged
  • Neuralgia / drug therapy
  • Safety*
  • Time Factors


  • Agmatine